- ASX-listed eHealth SaaS Company Respiri Limited filed for an additional patent application for asthma management device- wheezo.
- The additional patent filing was based on advancements made to the wheezo™ algorithm during the previous six months.
- Respiri said that the protection of its commercial advantage is significant as the Company aims for commercial launch in Australia, and then in Europe (including the UK), and the US over the next two years.
An eHealth SaaS company, Respiri Limited (ASX:RSH), announced the filing of an additional patent application for its asthma management device- wheezo™. The Company filed a patent application based on the considerable enhancements made by the development team in the wheezo™ algorithm during the last six months.
On 29 October 2020, the share price of RSH was noted at A$0.170 with a market capitalisation of almost A$114.24 million at AEST 4:26 PM.
Let us dive deep and discuss-
About Respiri Limited
ASX listed e-Health SaaS company Respiri Limited is engaged in providing support to respiratory health management. Respiri’s world-first technology detects wheeze, which is a typical symptom of COPD, asthma, and respiratory indications. The Company is working with a mission to improve asthma management by offering care beyond the clinic.
Respiri Files Patent for Next Generation wheezo™ algorithm
On 29 October 2020, Respiri Limited announced the filing of an additional patent application based on advancements made to the wheezo™ algorithm for the previous six months by the development team of the Company.
The additional Intellectual Property relates principally to a method of processing recordings of breathing of the subject. The method involves an analysis algorithm that processes the sound signal and marks periods containing pitch that is characteristic of wheeze through the trachea while simultaneously eliminating the background noise. By this means, the device delivers an improved level of detection that is a standardised and reproducible measure of wheeze.
The Company also stated that the protection of its commercial advantage is essential as it moves into commercial launch in Australia. Further, the Company has plans to launch into Europe, the UK, and the US over the next 12-24 month period.
CEO and Managing Director of Respiri Mr Marjan Mikel commented-
wheezo™ in Brief
Respiri developed wheezo™ in Australia, with the support of respiratory specialists along with some other healthcare professionals. The innovative wheezo™ device records wheeze, and the eHealth App helps patients to manage their asthma by tracking symptoms, triggers, medication use as well as geo-specific weather conditions.
The platform has been developed for extending the management of asthma beyond the clinic and make it easy to share information with physicians and make suitable modifications to asthma action plans.
Respiri’s wheezo™ algorithm is the only asthma management device that shows a high correlation to the gold standard, stethoscope measurement of wheeze through the back or chest. Further protections of its commercial advantage would put the Company in a strong position as it undertakes commercial plans across Australia, the US and Europe.